IMCR
Immunocore Holdings plcPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 25 ▲ Immunocore reported strong financial results for Q4 and full year 20…
- Apr 19 ▲ Immunocore announced five-year overall survival data from a Phase 3…
- May 31 ▲ Immunocore presented updated Phase 1 data for brenetafusp in heavily…
- Sep 14 ▲ Immunocore announced it has achieved target enrollment of 540 patien…
- Oct 15 FDA: Immunocore announces first patient dosed in the Phase 1 tr…
- Oct 29 FDA: Immunocore will present Phase 1 data for brenetafusp plus…
- Nov 6 FDA: Immunocore presents promising data from Phase 1/2 trial co…
- Nov 6 ▼ Earnings: IMCR Q3 2026 Earnings: EPS $-0.28 (-104.1% vs est)
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q2 2026: 18 added (0 new), 14 trimmed or exited.
- AnalystsBULLISH
14 of 19 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.171 → −$0.194 over 90 days. 1 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −0.1% to 7.79M shares. 14.2 days to cover, ≈15.1% of shares.
- TrendRANGE
7% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| MILLENNIUM MANAGEMENT LLC | ADD | $50.7M |
| BlackRock, Inc. | ADD | $31.9M |
| MARSHALL WACE, LLP | DOUBLED | $18.8M |
| CITADEL ADVISORS LLC | DOUBLED | $18.0M |
| Candriam S.C.A. | ADD | $11.8M |
| Legal & General Group Plc | ADD | $9.5M |
| MORGAN STANLEY | TRIM | $6.0M |
| Caption Management, LLC | TRIM | $5.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
19 analystsPrice is below the lowest target. Median implies +99%.Targets as of Nov 16, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 13, 2026 | Morgan Stanley MAINTAIN | Equal-Weight |
| Nov 10, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Oct 26, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Aug 3, 2026 | Mizuho MAINTAIN | Neutral |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Herbst Roy Steven Director May 27, 2026 | AWARD | 27,492 sh |
Bell John Irving Director May 27, 2026 | AWARD | 27,492 sh |
Peterson Kristine Director May 27, 2026 | AWARD | 27,492 sh |
Ratcliffe Peter John Director May 27, 2026 | AWARD | 27,492 sh |
Pao William Director May 27, 2026 | AWARD | 27,492 sh |
Kaul Siddharth Director May 27, 2026 | AWARD | 27,492 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.19 | -$0.44–$0.01 | -8.2% | $112.3M |
| Next Q | -$0.11 | -$0.22–-$0.03 | -19.1% | $119.9M |
| Current FY | -$0.20 | -$0.32–-$0.03 | -390.1% | $437.2M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
8 filings · 6 press releases · 2 bullish · 1 bearish · 1 mixed · 4 neutral- NEUTRAL SC 13GNov 9, 2026
Point72 Asset Management, L.P. (Steven Cohen's firm) filed a new Schedule 13G disclosing a 5.2%…
Point72's new 5.2% passive stake signals conviction in Immunocore's pipeline, particularly the Phase 3 TEBE-AM trial with topline OS data expected Q2 2027. Monitor for any future 13D conversion or…
- NEUTRAL PRESS RELEASENov 6, 2026
Immunocore presented Phase 1/2 data at SITC 2026 for brenetafusp alone and in combination with…
The combination data are encouraging but from a small sample; the key catalyst is the Phase 3 TEBE-AM trial in cutaneous melanoma with topline OS data expected Q2 2027. Monitor DUET-UVEAL trial…
- NEUTRAL 8-KNov 6, 2026
Immunocore reported Q3 2026 KIMMTRAK net revenue of $102.2M, down 1.4% YoY from $103.7M, but…
The TEBE-AM data readout in Q2 2027 is the next major catalyst; the flat reported revenue vs consensus of $113.4M may weigh on the stock near-term, but the company's cash runway and pipeline…
- BEARISH PRESS-RELEASENov 6, 2026
Immunocore reported Q3 2026 net product revenue of $102.2M, slightly below the $103.7M in Q3 2025…
Revenue came in below consensus, and the net loss was larger than expected. The company's guidance for ~$120M in rebate payments in Q4 2026 could pressure near-term cash flow. However, the pipeline…
All IMCR filing & press-release reports (14)
- SC 13G reportNov 9, 2026
- PRESS-RELEASE reportNov 6, 2026
- 8-K reportNov 6, 2026
- PRESS-RELEASE reportNov 6, 2026
- PRESS-RELEASE reportOct 29, 2026
- PRESS-RELEASE reportOct 15, 2026
- SC 13G/A reportOct 7, 2026
- 8-K reportSep 14, 2026
- 8-K reportAug 6, 2026
- PRESS-RELEASE reportMay 31, 2026
- PRESS-RELEASE reportApr 19, 2026
- 144 reportApr 8, 2026
- PRESS-RELEASE reportMar 17, 2026
- 8-K reportFeb 25, 2026